Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102â€™s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-24	CA$0.5100	0.00%	13,500
26-08-21	CA$0.5100	+2.00%	30,000
26-08-20	CA$0.5000	-9.09%	205,666

Delayed Quote Toronto S.E.

More quotes

Net sales - Rate of surprise

Company calendar

Market Closed - Toronto S.E. 10:58:34 2026-08-24 am EDT			5-day change	1st Jan Change
0.5100 ^CAD	0.00%		-7.27%	-21.54%

Aug. 06	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jul. 13	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI

Market Cap	35.69M 25.78M 22.09M 20.7M 18.91M 2.46B 36.04M 244M 95.07M 1.24B 96.82M 94.71M 4.11B	P/E 2024	-8.65x	P/E 2025	-4.25x
Enterprise Value	34.07M 24.62M 21.09M 19.77M 18.05M 2.35B 34.41M 233M 90.76M 1.18B 92.43M 90.42M 3.92B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	85.91%	Yield 2024 *	-	Yield 2025	-

Aug. 06	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jul. 13	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI
Jul. 13	Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation	MT
Jun. 17	Thiogenesis Therapeutics Appoints Gilad Aharon to its Board	MT
Jun. 17	Thiogenesis Therapeutics, Corp. Appoints Gilad Aharon to Its Board of Directors	CI
Jun. 03	Thiogenesis Therapeutics, Corp. announced that it has received CAD 9.07185 million in funding	CI
May. 25	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 11	Thiogenesis Therapeutics to Raise $8 Million Via a Non-Brokered Private Placement	MT
May. 11	Thiogenesis Therapeutics, Corp. announced that it expects to receive CAD 8 million in funding	CI
Apr. 30	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Apr. 29	Thiogenesis Therapeutics, Corp. Auditor Raises 'Going Concern' Doubt	CI
Feb. 02	Thiogenesis Therapeutics, Corp. Provides Program Update	CI
Jan. 23	Thiogenesis Therapeutics, Corp. Announces the Presentation of Interim Data from Its Phase 2 (Eu) Clinical Study of Tti-0102 in Patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes At Mitocon 2026	CI

Jul. 13	Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome	NE
Jun. 17	Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors	NE
Jun. 03	Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million	NE
Jun. 01	Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares	NE
May. 11	Thiogenesis Announces Non-Brokered Private Placement	NE

Thiogenesis Therapeutics, Corp. Stock

Stocks

TTI

CA88410L1022

Biotechnology & Medical Research

Valuation: Thiogenesis Therapeutics, Corp.

Chart: Thiogenesis Therapeutics, Corp.

Latest news : Thiogenesis Therapeutics, Corp.

Analysts' recommendations: Thiogenesis Therapeutics, Corp.

Press Releases: Thiogenesis Therapeutics, Corp.

Quotes and Performance

Price Extremes

Managers and Directors: Thiogenesis Therapeutics, Corp.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Net sales - Rate of surprise

1 week	-7.27%
Current month	-5.56%
1 month	-3.77%
3 months	-15.00%
6 months	-8.93%
Current year	-21.54%

1 week	0.5	0.52
1 month	0.5	0.58
Current year	0.44	0.66
1 year	0.44	0.81
3 years	0.44	1.06
5 years	0.38	1.06
10 years	0.38	1.06

Manager	Title	Age	Since
Patrice Rioux CEO	Chief Executive Officer	75	2022-03-30
Brook Riggins CEO	Chief Executive Officer	60	-

Director	Title	Age	Since
Christopher Starr CHM	Chairman	73	2022-03-30
Patrice Rioux BRD	Director/Board Member	75	2022-03-30
Brook Riggins BRD	Director/Board Member	60	2018-05-02

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/11/25	W. Mullally	Option	Director	75,000	0.1702%
8/1/25	W. Mullally	Sell	Director	64,000	0.1453%
6/12/25	Christopher Starr	Option	Chairman	200,000	0.4540%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THIOGENESIS THERAPEUTICS, CORP.	0.00%	-7.27%	-35.44%	-27.14%	25.78M
LONZA GROUP AG	-0.19%	+2.49%	+2.66%	+24.84%	51.65B
REVOLUTION MEDICINES, INC.	-0.09%	-2.14%	+492.60%	+537.84%	45.31B
IQVIA HOLDINGS INC.	-0.32%	+8.08%	+37.97%	+18.45%	42.7B
BEONE MEDICINES AG	+1.18%	+1.96%	+21.95%	+89.69%	42.79B
CELLTRION, INC.	-2.27%	-3.02%	+14.22%	+51.50%	32.87B
MEDPACE HOLDINGS, INC.	-0.96%	+4.03%	+31.55%	+136.34%	17.14B
ASCENDIS PHARMA A/S	+0.41%	+1.66%	-	-	16.61B
EUROFINS SCIENTIFIC SE	+0.13%	+4.95%	+13.15%	+30.93%	15.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.31%	+6.61%	+81.37%	+48.53%	14.21B
Average	-0.24%	+1.95%	+73.34%	+101.22%	27.83B
Weighted average by Cap.	-0.21%	+2.74%	+104.61%	+135.49%

	2024	2025
Net sales	-	-
Net income	-3.15M -2.27M -1.95M -1.82M -1.67M -217M -3.18M -21.52M -8.38M -109M -8.53M -8.35M -362M	-7.43M -5.37M -4.6M -4.31M -3.93M -511M -7.5M -50.81M -19.78M -258M -20.14M -19.71M -855M
Net Debt	-3.85M -2.78M -2.38M -2.23M -2.04M -265M -3.89M -26.33M -10.25M -134M -10.44M -10.21M -443M	-1.62M -1.17M -1M -937K -856K -111M -1.63M -11.06M -4.3M -56.15M -4.38M -4.29M -186M